<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00192452</url>
  </required_header>
  <id_info>
    <org_study_id>MI-CP074</org_study_id>
    <nct_id>NCT00192452</nct_id>
  </id_info>
  <brief_title>Study of MEDI-507 Administered by Intravenous Infusion to Adults With Plaque Psoriasis</brief_title>
  <official_title>A Phase II Randomized, Double-Blind, Placebo-Controlled Study of MEDI-507, a Humanized Monoclonal Antibody That Binds to the CD2 Receptor, Administered by Intravenous Infusion to Adults With Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <brief_summary>
    <textblock>
      - The primary objective of this study is to compare disease activity, as measured by PASI
      score, of two MEDI-507 dose levels (0.012 and 0.04 mg/kg) versus placebo administered by
      intravenous infusion every 2 weeks for a total of 8 infusions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2001</start_date>
  <completion_date>December 2001</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analyses of categorical data will be performed and analysis of continuous data will be performed using a one-way analysis of variance (ANOVA) with traetment group as a factor.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with at least 75% improvement and those with at least 50% improvement will be compared.</measure>
  </secondary_outcome>
  <enrollment>120</enrollment>
  <condition>Psoriasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-507</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Plaque psoriasis involving at least 10% of body surface area (Appendix B)

          -  Age 18 through 65 years at the time of the first dose of study drug

          -  Both males and females are eligible. However, sexually active females, unless
             surgically sterile or at least 1 year post-menopausal, must have used an effective
             method of avoiding pregnancy (including oral or implanted contraceptives, IUD, female
             condom, diaphragm with spermicide, cervical cap, abstinence, use of a condom by the
             sexual partner or sterile sexual partner) for 30 days prior to the first dose of study
             drug and must agree to continue using such precautions for 60 days after the final
             dose of study drug

          -  Currently receiving no therapy for psoriasis except emollients (certain other
             over-the-counter products may be allowed with prior approval of the sponsor)

          -  Written informed consent obtained from the patient

          -  Ability to complete follow-up period of 188 days as required by the protocol

        Exclusion Criteria:

          -  Pustular, guttate, or erythrodermic psoriasis as the predominant disease type

          -  PASI score &lt;8

          -  At screening (must be within 21 days before study entry) any of the following:
             lymphocyte count under 1,200 cells/mm3, WBC under 4,000 cells/mm3, hematocrit below
             32%, platelets below 110,000 cells/mm3, creatinine, AST, ALT over 1.5 times upper
             limit of normal

          -  At screening (must be within 21 days before study entry) any clinical evidence of HIV,
             hepatitis B, hepatitis C or active hepatitis A infection

          -  Pregnancy (must have a negative serum pregnancy test within 21 days prior to the first
             dose of study drug, and urine pregnancy test must be negative on Study Day 0 before
             study entry)

          -  History of cancer (except excision of basal cell carcinoma)

          -  Any documented immunodeficiency

          -  A history of prior administration of monoclonal antibodies or related proteins, with
             the exception of MEDI-507 (Note: prior recipients of MEDI-507 will require review and
             approval by the sponsor prior to entry)

          -  Receipt of systemic retinoids, corticosteroids, cyclosporin A, methotrexate,
             phototherapy or coal tar treatment in the past 4 weeks

          -  Use of topical therapy (except emollients) for psoriasis in the past 2 weeks (certain
             other over-the-counter products may be allowed with prior approval of the sponsor)

          -  Receipt of any investigational drug therapy within 6 weeks before the first dose of
             study drug in this protocol (use of licensed agents for indications not listed in the
             package insert is permitted)

          -  Current or planned participation in a research protocol in which an investigational
             agent or therapy may be administered

          -  Nursing mother

          -  Acute illness including infections

          -  Clinical manifestations of significant end organ dysfunction or failure that may
             compromise the safety of the volunteer in the study

          -  A known drug allergy or medical contraindication to ibuprofen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stanley Pillemer, MD</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MDS Pharma Services (US) Inc.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University School of Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Kinetics</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>October 23, 2006</last_update_submitted>
  <last_update_submitted_qc>October 23, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2006</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

